查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924709

猴痘抗原檢測試劑市場按產品類型、技術、檢測類型、檢體類型和最終用戶分類－2026-2032年全球預測

Monkeypox Antigen Test Reagent Market by Product Type, Technology, Test Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年猴痘抗原檢測試劑市值為 1.4514 億美元，預計到 2026 年將成長至 1.6627 億美元，到 2032 年預計將達到 3.2135 億美元，複合年成長率為 12.02%。

關鍵市場統計數據
基準年 2025 1.4514億美元
預計年份：2026年 1.6627億美元
預測年份 2032 3.2135億美元
複合年成長率 (%) 12.02%

本文簡要概述了目前抗原試劑的現狀，並探討了影響猴痘診斷策略的技術、監管和操作因素。

猴痘已成為新的診斷重點領域，加速了抗原檢測方法和整體診斷流程的創新。本執行摘要介紹了目前抗原檢測試劑的現狀，重點闡述了影響採購和實施決策的技術差異、最終用戶需求和操作限制。文中也提供了相關背景資訊，幫助讀者理解不同醫療機構中的檢測形式、設備和檢體處理方法如何與監管途徑和臨床效用相互關聯。

診斷技術研發、監管方法和供應鏈預期的重大系統性變革正在重新定義抗原試劑的創新和應用。

技術進步、終端用戶需求的變化以及供應鏈重組正在推動多重變革，重塑抗原試劑生態系統。在許多情況下，照護現場能力已從“理想”變為“必需”，促使製造商優先考慮側向流動檢測形式和簡化的工作流程，以減少對集中式檢查室基礎設施的依賴。同時，生物感測器靈敏度的提高和微流體整合技術的進步，使得更複雜的檢測模式成為可能，這些模式與傳統的酶聯免疫吸附試驗 (ELISA) 相輔相成，促進了兼顧速度和分析嚴謹性的混合工作流程的形成。

不斷變化的關稅制度和貿易政策趨勢正在推動供應鏈重組、在地化和策略採購，以確保試劑供應穩定並維持利潤率。

影響跨境貿易和進口關稅的政策行動對試劑供應、價格波動和生產策略有重大影響。關稅上調會直接增加進口零件和成品的到岸成本，擠壓利潤空間，並可能促使企業採取即時採購模式，從而減少庫存緩衝。為此，許多生產商和採購商正在加快採購多元化的步伐，評估區域生產能力，並重新談判供應契約，以減少對單一供應商的依賴。隨著時間的推移，這些調整往往會將採購重心轉移到擁有國內或鄰近採購能力的供應商。同時，依賴全球供應商網路的企業則被要求加強合約保障措施和緊急時應對計畫。

將產品架構、檢測技術、最終用戶畫像、測試方法和檢體類型與策略發展和採購選擇聯繫起來的詳細細分分析

深度細分分析揭示了技術選擇、臨床工作流程和採購行為之間的交集，從而影響試劑部署和產品開發優先順序。相關人員應根據產品類型評估分析儀器和檢測套組之間的差異。分析儀器包括側向流讀取儀和微孔盤讀數儀，它們具備定量和高通量檢測能力；而檢測套組則包括生物感測器試劑盒、ELISA試劑盒和側向層析試劑盒，這些試劑盒針對不同的操作環境而設計。這些差異會影響買方對通量、連接性和檢驗數據的要求，並決定製造商為將其檢測方法整合到臨床路徑中而尋求的夥伴關係類型。

從區域視角比較美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、採用促進因素和供應鏈現狀

區域趨勢將對美洲、歐洲、中東和非洲以及亞太地區的採納路徑、監管參與和供應鏈配置產生重大影響。在美洲，醫療保健系統尤其重視快速採納並與現有臨床工作流程整合，從而推動了對就地檢驗和儀器化側向層析解決方案的需求，這些解決方案能夠提供及時的臨床資訊。該地區的支付和採購機制傾向於選擇可擴展的解決方案，這些解決方案需展現出明確的臨床效用和與實驗室資訊系統的兼容性。

製造商、創新者和通路合作夥伴之間的競爭行為和策略聯盟決定了產品的覆蓋範圍、檢驗成功率和供應可靠性。

抗原試劑領域的競爭格局呈現出多元化的特點，既有成熟的診斷公司，也有靈活的利基創新者、契約製造和能夠實現快速檢測部署的平台提供者。主要企業強調整合價值提案，將試劑產品組合、儀器平台和數位化結果管理結合，透過捆綁式產品和服務協議鎖定機構客戶。小規模的公司則往往透過技術新穎性脫穎而出，例如增強型生物感測器化學和微流體整合，並致力於開發快速診斷能夠帶來可衡量的臨床和營運效益的特定應用場景。

產業領導者應採取哪些切實可行的策略步驟和營運投資，以提高抗原試劑的穩定性、加速應用推廣並增強臨床效用？

產業領導者應優先採取一系列重點突出、切實可行的措施，以增強韌性並加速技術應用。首先，投資於模組化平台設計，使相同的底層化學原理能夠應用於側向流動、生物感測器和微流體多種技術，從而加快產品上市速度，並為不同的檢測方法提供靈活的生產方式。其次，擴大與代表性終端使用者（診所、醫院檢查室、獨立診斷中心和研究機構）的檢驗夥伴關係，收集各種檢體類型（包括血漿、唾液、血清、拭子和全血）的性能數據，確保使用說明能反映實際工作流程。

一項透明的、三角驗證的研究途徑，結合了相關人員訪談、檢查室證據審查和政策分析，對診斷性能和供應鏈的說法檢驗。

本分析整合了結構化調查方法的研究成果，該方法結合了關鍵相關人員的對話、檢查室檢驗審查和系統的二手研究。關鍵投入包括對診斷開發人員、臨床檢查室主任、採購負責人和監管專家的深入訪談，以了解不同終端使用者環境下的決策標準、檢驗方法和採購限制。檢查室檢驗審查側重於同行評審出版物、監管申報文件和製造商技術文件中的測試性能特徵、與檢體類型的兼容性以及設備整合要求。

整合診斷優先事項、技術權衡和戰略要務，這將決定試劑的成功應用和長期應用。

總之，猴痘抗原試劑的現狀正處於技術創新、不斷變化的監管環境和不斷變化的供應鏈動態的交匯點。診斷決策者必須權衡快速分散檢測的需求與分析穩健性和互通性的要求。技術方法已分化為兩種：一種是優先考慮可及性的快速側向層析法，另一種是支援高靈敏度和高通量的儀器化檢測方法。這兩種方法的重要性將取決於臨床應用場景和醫療環境。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 猴痘抗原檢測試劑市場（依產品類型分類）

  • 分析設備
    • 側向流讀取儀
    • 微孔盤讀數儀
  • 檢測套組
    • 生物感測器套件
    • ELISA試劑盒
    • 側向流動試劑盒

9. 依技術分類的猴痘抗原檢測試劑市場

  • 生物感測器
  • 酵素免疫分析法
    • 比色法
    • 螢光檢測法
  • 橫向流動化驗
    • 膠體金側向流動
    • 螢光側向流動
  • 微流體技術

第10章 猴痘抗原檢測試劑市場（依檢測類型分類）

  • 檢查室檢測
  • 快速檢測
    • 就地檢驗
    • 自我檢查

第11章 依檢體類型分類的猴痘抗原檢測試劑市場

  • 電漿
  • 唾液
  • 血清
  • 拭子
  • 全血

第12章：猴痘抗原檢測試劑市場（依最終用戶分類）

  • 診所
  • 診斷檢查室
  • 醫院
    • 公立醫院
    • 私立醫院
  • 研究所

第13章 猴痘抗原檢測試劑市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 猴痘抗原檢測試劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國猴痘抗原檢測試劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國猴痘抗原檢測試劑市場

第17章：中國猴痘抗原檢測試劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Autobio Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • BTNX, Inc.
  • CerTest Biotec SL
  • Era Biology Co., Ltd.
  • Getein Biotech, Inc.
  • Hangzhou Clongene Biotech Co., Ltd.
  • Hotgen Biotech Co., Ltd.
  • InTec Products, Inc.
  • JOYSBIO Biotechnology Co., Ltd.
  • Nanjing Poclight Biotechnology Co., Ltd.
  • Roche Diagnostics GmbH
  • Siemens Healthineers AG
  • Sino Biological Inc.
  • Virax Biolabs Ltd.
Product Code: MRR-7A380DA7C440

The Monkeypox Antigen Test Reagent Market was valued at USD 145.14 million in 2025 and is projected to grow to USD 166.27 million in 2026, with a CAGR of 12.02%, reaching USD 321.35 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 145.14 million
Estimated Year [2026] USD 166.27 million
Forecast Year [2032] USD 321.35 million
CAGR (%) 12.02%

A concise orientation to the antigen reagent landscape that contextualizes technical, regulatory, and operational drivers influencing diagnostic strategies for monkeypox

The emergence of monkeypox as an area of renewed diagnostic focus has accelerated innovation across antigen detection modalities and diagnostic workflows. This executive summary introduces the contemporary landscape for antigen test reagents, framing the discussion around technological differentiation, end-user requirements, and operational constraints that shape procurement and deployment decisions. It situates the reader to understand how assay formats, instrumentation, and sample handling interrelate with regulatory pathways and clinical utility in varied care settings.

The narrative that follows synthesizes observable dynamics across product types and testing technologies, examines the implications of evolving trade and tariff environments, and highlights the strategic pressures affecting manufacturers, distributors, and service providers. Throughout, the emphasis is on translating complex technical and policy developments into clear implications for stakeholders involved in diagnostics design, supply chain management, and public health preparedness. By foregrounding practical considerations such as turnaround time, ease of use, and compatibility with existing laboratory infrastructure, this introduction sets the stage for a deeper analysis of shifts, segmentation nuances, regional characteristics, and tactical recommendations that can inform near-term decisions and longer-term capability building.

Critical systemic changes in diagnostic development, regulatory approaches, and supply chain expectations that are redefining antigen reagent innovation and adoption

Several transformative shifts are reshaping the antigen reagent ecosystem, driven by technological advances, shifting end-user expectations, and supply chain realignment. Point-of-care readiness has moved from desirable to essential in many settings, prompting manufacturers to prioritize lateral flow formats and simplified workflows that reduce dependence on centralized laboratory infrastructure. Concurrently, improvements in biosensor sensitivity and microfluidic integration are enabling more nuanced detection paradigms that can complement traditional enzyme-linked approaches, fostering hybrid workflows that balance speed and analytical rigor.

Regulatory environments are also evolving to accommodate accelerated review pathways for high-priority diagnostics, which in turn influences development timelines and go-to-market strategies. At the same time, procurement and reimbursement frameworks are increasingly calibrated to emphasize clinical utility and cost-effectiveness, encouraging vendors to demonstrate clear patient outcome benefits. Finally, data integration expectations are rising: stakeholders now demand interoperable reporting, digital result capture, and analytics-ready outputs that support surveillance and provider decision-making. Together, these shifts create both opportunity and pressure, compelling organizations to invest in flexible platforms, robust validation, and partnerships that bridge technology, clinical adoption, and supply resilience.

How evolving tariff regimes and trade policy dynamics are prompting supply chain realignment, localization, and strategic sourcing to preserve reagent access and margin stability

Policy measures affecting cross-border trade and import duties have material implications for reagent availability, pricing dynamics, and manufacturing strategies. When tariffs increase, they directly raise landed costs for imported components and finished products, which can compress margins and incentivize just-in-time procurement that reduces inventory buffers. In response, many producers and purchasers accelerate efforts to diversify sourcing, evaluate regional manufacturing capacity, and renegotiate supply agreements to mitigate single-source dependencies. Over time, such adjustments typically shift procurement toward suppliers with domestic or nearshore capabilities when available, while firms reliant on global supplier networks must strengthen contractual protections and contingency planning.

Tariff-driven cost pressures also influence investment decisions related to automation, localization of production lines, and partnerships with contract manufacturers. Diagnostic developers may prioritize modular platforms that can be produced in multiple geographies to reduce exposure to trade volatility. In parallel, distributors and health systems reassess SKU rationalization and inventory strategies to preserve access without incurring unsustainable expense. Importantly, compliance obligations and customs complexity introduce administrative overhead that favors suppliers with established global logistics expertise. In short, tariff dynamics act as a catalyst for supply chain realignment, supplier consolidation in some segments, and accelerated emphasis on manufacturing agility and contractual risk management.

In-depth segmentation analysis connecting product architectures, detection technologies, end-user profiles, test modalities, and specimen types to strategic development and procurement choices

Deep segmentation reveals where technology choices, clinical workflows, and purchasing behaviors intersect to shape reagent deployment and product development priorities. Based on product type, stakeholders must weigh differences between analytical instruments and test kits: analytical instruments encompass lateral flow readers and microplate readers that add quantitative or higher-throughput capability, while test kits include biosensor kits, ELISA kits, and lateral flow kits designed for varying operational contexts. These distinctions influence buyer requirements for throughput, connectivity, and validation data, and they determine the types of partnerships that manufacturers pursue to embed their assays into clinical pathways.

Based on technology, developers navigate trade-offs among biosensors, enzyme-linked immunosorbent assays, lateral flow assays, and microfluidics. Enzyme-linked formats are subdivided into colorimetric and fluorometric readouts that differ in sensitivity and instrumentation needs, whereas lateral flow assays split into colloidal gold and fluorescence lateral flow formats, each with distinct detection thresholds and manufacturing considerations. Based on end user, the landscape spans clinics, diagnostic laboratories, hospitals, and research institutes; clinics include community and outpatient clinics, diagnostic laboratories encompass hospital and independent labs, and hospitals may be government or private. These end-user distinctions drive purchasing cycles, validation expectations, and required service models. Based on test type, the spectrum ranges from laboratory tests to rapid tests; laboratory tests further separate into automated and manual assays, while rapid tests distinguish point-of-care tests from self-tests, reflecting divergent regulatory and usability requirements. Finally, based on sample type, performance and logistics are shaped by the use of plasma, saliva, serum, swab, and whole blood, each imposing specific collection, transport, and storage conditions that influence kit formulation and instructions for use.

Comparative regional outlook highlighting regulatory diversity, adoption drivers, and supply chain realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence adoption pathways, regulatory interactions, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, health systems exhibit a pronounced focus on rapid deployment and integration with existing clinical workflows, driving demand for point-of-care and instrumented lateral flow solutions that provide timely clinical information. Payment and procurement mechanisms in this region often favor scalable solutions that demonstrate clear clinical utility and compatibility with laboratory information systems.

Europe, the Middle East & Africa present a heterogeneous regulatory and operational environment where harmonization and cross-border procurement patterns vary considerably. In parts of Europe, centralized regulatory scrutiny emphasizes analytical performance and post-market surveillance, while resource variability across the Middle East & Africa shapes demand for low-cost, robust formats that tolerate supply chain variability. In the Asia-Pacific region, significant manufacturing capacity coexists with diverse adoption curves; some markets prioritize high-throughput laboratory solutions and automation, while others accelerate point-of-care and self-test availability to expand access. Across all regions, interoperability, regulatory alignment, and supply reliability remain central determinants of successful product introduction and sustained uptake.

Competitive behaviors and strategic alignments among manufacturers, innovators, and channel partners that determine product reach, validation success, and supply reliability

Competitive dynamics in the antigen reagent arena are characterized by a mix of established diagnostics firms, agile niche innovators, contract manufacturers, and platform providers that enable rapid assay deployment. Leading organizations emphasize integrated value propositions that combine reagent portfolios with instrument platforms and digital result management, seeking to lock in institutional customers through bundled offerings and service contracts. Smaller companies often differentiate through technological novelty-such as enhanced biosensor chemistries or microfluidic integration-and by pursuing targeted use cases where rapid diagnostics can demonstrate measurable clinical or operational benefit.

Strategic behaviors observed include licensing arrangements that accelerate market entry, co-development partnerships with clinical laboratories to ensure real-world validation, and manufacturing scale-up agreements to manage capacity constraints. Additionally, companies increasingly pursue regulatory harmonization strategies, compiling evidence packages designed to align with multiple jurisdictions' requirements. Distribution partnerships and channel diversification are also vital, as access to healthcare networks and procurement entities determines uptake. Taken together, these behaviors indicate an industry balancing the need for rigorous validation with the urgency of deployment, where collaboration across clinical, commercial, and manufacturing domains is a prerequisite for success.

Practical strategic moves and operational investments that industry leaders should implement to improve resilience, expedite adoption, and strengthen clinical utility of antigen reagents

Industry leaders should prioritize a set of focused, actionable initiatives to strengthen resilience and accelerate adoption. First, invest in modular platform designs that enable the same underlying chemistry to be configured across lateral flow, biosensor, and microfluidic formats, thereby reducing time-to-market for variant assays and enabling flexible manufacturing. Second, expand validation partnerships with representative end users-clinics, hospital laboratories, independent diagnostic centers, and research institutes-to collect diverse performance data across sample types such as plasma, saliva, serum, swab, and whole blood, ensuring that instructions for use reflect real-world workflows.

Third, fortify supply chains by qualifying alternate suppliers, exploring regional manufacturing or contract manufacturing partnerships, and incorporating tariff exposure into procurement contracts to dampen cost volatility. Fourth, enhance product appeal through integration with digital reporting and result capture, improving interoperability with laboratory information systems and public health surveillance platforms. Fifth, engage early with regulatory authorities to clarify evidence expectations for different test types, whether automated laboratory assays or point-of-care devices, and to expedite pathways for emergency or prioritized review when appropriate. Finally, align commercial strategies to emphasize bundled service offerings, training, and technical support that reduce barriers to adoption in resource-constrained settings and foster long-term customer relationships.

A transparent, triangulated research approach combining stakeholder interviews, laboratory evidence review, and policy analysis to validate diagnostic performance and supply chain assertions

This analysis synthesizes insights derived from a structured research methodology combining primary stakeholder engagement, laboratory validation review, and systematic secondary research. Primary inputs included in-depth interviews with diagnostic developers, clinical laboratory directors, procurement officers, and regulatory specialists to capture decision-making criteria, validation practices, and procurement constraints across diverse end-user settings. Laboratory validation review focused on assay performance characteristics, sample type compatibility, and instrument integration requirements drawn from peer-reviewed publications, regulatory filings, and manufacturer technical dossiers.

Secondary research involved cross-referencing publicly available regulatory guidance, trade policy publications, and industry white papers to contextualize tariff and supply chain dynamics. Evidence was triangulated through multiple sources to reduce bias and to validate technical claims. Wherever feasible, claims about assay performance were corroborated against independent evaluations and regulatory summaries rather than vendor promotional materials. The methodology recognizes limitations related to rapidly evolving policy environments and the proprietary nature of some commercial agreements, and therefore emphasizes transparent sourcing and conservative interpretation of commercially sensitive assertions.

Synthesis of diagnostic priorities, technological trade-offs, and strategic imperatives that will determine successful reagent deployment and long-term adoption

In conclusion, the antigen reagent landscape for monkeypox represents a confluence of technological innovation, regulatory evolution, and shifting supply chain dynamics. Diagnostic decision-makers must balance the need for rapid, decentralized testing with requirements for analytical robustness and interoperability. Technological pathways diverge between rapid lateral flow approaches that prioritize accessibility and instrumented assays that support higher sensitivity and throughput, and both paths will remain relevant depending on the clinical use case and care setting.

Strategic resilience will come from flexible platform design, diversified manufacturing footprints, and deeper engagement with end users to ensure that assay formats meet operational needs across clinics, hospitals, diagnostic laboratories, and research institutes. Policy environments, including tariff dynamics and regulatory adjustments, further underscore the importance of agility in supplier selection and contractual risk management. Ultimately, organizations that integrate rigorous validation, supply chain foresight, and clear value propositions tied to clinical outcomes will be best positioned to support effective diagnostic responses and sustained adoption in varied healthcare contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Monkeypox Antigen Test Reagent Market, by Product Type

  • 8.1. Analytical Instrument
    • 8.1.1. Lateral Flow Reader
    • 8.1.2. Microplate Reader
  • 8.2. Test Kit
    • 8.2.1. Biosensor Kit
    • 8.2.2. Elisa Kit
    • 8.2.3. Lateral Flow Kit

9. Monkeypox Antigen Test Reagent Market, by Technology

  • 9.1. Biosensor
  • 9.2. Enzyme Linked Immunosorbent Assay
    • 9.2.1. Colorimetric
    • 9.2.2. Fluorometric
  • 9.3. Lateral Flow Assay
    • 9.3.1. Colloidal Gold Lateral Flow
    • 9.3.2. Fluorescence Lateral Flow
  • 9.4. Microfluidics

10. Monkeypox Antigen Test Reagent Market, by Test Type

  • 10.1. Laboratory Test
  • 10.2. Rapid Test
    • 10.2.1. Point Of Care Test
    • 10.2.2. Self Test

11. Monkeypox Antigen Test Reagent Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Saliva
  • 11.3. Serum
  • 11.4. Swab
  • 11.5. Whole Blood

12. Monkeypox Antigen Test Reagent Market, by End User

  • 12.1. Clinic
  • 12.2. Diagnostic Laboratory
  • 12.3. Hospital
    • 12.3.1. Government Hospital
    • 12.3.2. Private Hospital
  • 12.4. Research Institute

13. Monkeypox Antigen Test Reagent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Monkeypox Antigen Test Reagent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Monkeypox Antigen Test Reagent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Monkeypox Antigen Test Reagent Market

17. China Monkeypox Antigen Test Reagent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Autobio Diagnostics Co., Ltd.
  • 18.6. Becton, Dickinson and Company
  • 18.7. BTNX, Inc.
  • 18.8. CerTest Biotec S.L.
  • 18.9. Era Biology Co., Ltd.
  • 18.10. Getein Biotech, Inc.
  • 18.11. Hangzhou Clongene Biotech Co., Ltd.
  • 18.12. Hotgen Biotech Co., Ltd.
  • 18.13. InTec Products, Inc.
  • 18.14. JOYSBIO Biotechnology Co., Ltd.
  • 18.15. Nanjing Poclight Biotechnology Co., Ltd.
  • 18.16. Roche Diagnostics GmbH
  • 18.17. Siemens Healthineers AG
  • 18.18. Sino Biological Inc.
  • 18.19. Virax Biolabs Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW READER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROPLATE READER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ELISA KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUOROMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COLLOIDAL GOLD LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY FLUORESCENCE LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LABORATORY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY POINT OF CARE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SELF TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GOVERNMENT HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 222. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 258. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. G7 MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 270. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ANALYTICAL INSTRUMENT, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST KIT, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY RAPID TEST, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA MONKEYPOX ANTIGEN TEST REAGENT MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)